Stockscreener 앱 받기
91.13
1.46%
-1.35
전일 마감가:
$92.48
열려 있는:
$92.15
하루 거래량:
12.77M
Relative Volume:
1.03
시가총액:
$158.35B
수익:
$45.13B
순이익/손실:
$6.28B
주가수익비율:
25.39
EPS:
3.5895
순현금흐름:
$7.40B
1주 성능:
-5.87%
1개월 성능:
-12.43%
6개월 성능:
-28.16%
1년 성능:
-29.56%
1일 변동 폭
$91.05
$92.66
1주일 범위
$90.72
$97.32
52주 변동 폭
$90.72
$139.06
애보트 래버러토리스 Stock (ABT) Company Profile
명칭
Abbott Laboratories
전화
(224) 667-6100
주소
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
91.13 | 158.35B | 45.13B | 6.28B | 7.40B | 3.5895 |
SYK
Stryker Corp
|
327.51 | 125.43B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
83.32 | 106.97B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.07 | 92.25B | 20.62B | 3.56B | 3.66B | 2.3847 |
EW
Edwards Lifesciences Corp
|
84.15 | 48.52B | 6.30B | 1.07B | 1.34B | 1.8406 |
애보트 래버러토리스 Stock (ABT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-10 | 개시 | The Benchmark Company | Buy |
| 2025-07-18 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-06-16 | 개시 | Leerink Partners | Market Perform |
| 2024-10-08 | 개시 | Oppenheimer | Outperform |
| 2024-09-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 다운그레이드 | Edward Jones | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2023-07-21 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | 재확인 | Barclays | Overweight |
| 2023-04-20 | 재확인 | Bernstein | Outperform |
| 2023-04-20 | 재확인 | JP Morgan | Overweight |
| 2023-04-20 | 재확인 | Raymond James | Outperform |
| 2023-04-20 | 재확인 | UBS | Buy |
| 2023-04-20 | 재확인 | Wolfe Research | Underperform |
| 2023-03-29 | 개시 | UBS | Buy |
| 2022-10-26 | 개시 | Mizuho | Neutral |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-07-06 | 개시 | Wolfe Research | Underperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-01-27 | 재확인 | Credit Suisse | Outperform |
| 2022-01-27 | 재확인 | Morgan Stanley | Overweight |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | UBS | Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-10-27 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | 개시 | Redburn | Neutral |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-01-28 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-09-11 | 개시 | Wolfe Research | Outperform |
| 2020-06-01 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-06-13 | 재확인 | BofA/Merrill | Buy |
| 2019-02-07 | 재확인 | BofA/Merrill | Buy |
| 2019-01-02 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-11-30 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-06-27 | 개시 | Bernstein | Outperform |
| 2018-01-30 | 재확인 | Citigroup | Neutral |
| 2018-01-25 | 재확인 | Stifel | Buy |
| 2018-01-25 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-01-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-19 | 재확인 | Stifel | Buy |
모두보기
애보트 래버러토리스 주식(ABT)의 최신 뉴스
Teachers Retirement System of The State of Kentucky Trims Stock Position in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Bought by Vanguard Group Inc. - MarketBeat
Commentary: There is a hidden cost to the Abbott verdict for premature babies - Daily Republic
Concurrent Investment Advisors LLC Purchases 17,137 Shares of Abbott Laboratories $ABT - MarketBeat
Why Abbott Laboratories stock tumbled on Thursday - MSN
Cardiac treatment advancements see Abbott Laboratories stock down 1.44% amid oversold signals and bearish pressure - Traders Union
Abbott Laboratories Q1 2026 Earnings: $2B CGM Quarter, 65% Upside Priced In - TIKR.com
Abbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026 - Abbott MediaRoom
4 new studies test Abbott devices for irregular heartbeats - Stock Titan
M&T Bank Corp Decreases Holdings in Abbott Laboratories $ABT - MarketBeat
Is There Now An Opportunity In Abbott Laboratories (ABT) After Recent Share Price Pullback? - simplywall.st
A Look At Abbott Laboratories ABT Valuation After New Cancerguard Early Cancer Detection Data - Yahoo Finance
Abbott Laboratories stock underperforms Friday when compared to competitors - MarketWatch
Daiwa Downgrades Abbott Laboratories (ABT), Sees Limited Upside - Yahoo Finance
Abbott Laboratories: Buying A Healthcare Giant On Sale (NYSE:ABT) - Seeking Alpha
Abbott Laboratories cuts outlook, says mild flu season hurt sales - MSN
Why Abbott’s S&P 500 Fund Oncology Story Is Turning Heads? - Kalkine Media
symbol__ Stock Quote Price and Forecast - CNN
Abbott CancerGuard Data And AACR Award Add To Oncology Growth Story - simplywall.st
Catheters Market Report 2025-2030, Profiles and Strategy Analysis of Leading PlayersAbbott Laboratories, Boston Scientific, Medtronic, Terumo, and B. Braun - Yahoo Finance
Abbott Laboratories $ABT Shares Purchased by B. Metzler seel. Sohn & Co. AG - MarketBeat
ABT (Abbott Laboratories) reports narrow Q1 2026 EPS miss as positive investor sentiment pushes shares up 1.4 percent.Open Stock Signal Network - Xã Thanh Hà
Coagulation Analyzer Market Size to Reach a Valuation of USD 7.87 Billion by 2035; Increasing Incidence of Blood Disorders to Propel Market Expansion Globally | SNS Insider - GlobeNewswire Inc.
Abbott Laboratories (ABT) Tops List of Oversold Healthcare Stocks - GuruFocus
Universal Beteiligungs und Servicegesellschaft mbH Sells 159,473 Shares of Abbott Laboratories $ABT - MarketBeat
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know - Yahoo Finance
Abbott is the most oversold healthcare stock as Q1 earnings roll on - MSN
Abbott Laboratories (NYSE:ABT) Downgraded by Daiwa Securities Group to Neutral - MarketBeat
KLP Kapitalforvaltning AS Cuts Stake in Abbott Laboratories $ABT - MarketBeat
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Abbott Laboratories, Airbnb, Biogen, Cava Group, GitLab, Halliburton, Qualcomm, Seagate, Toast, and More - Yahoo Finance
TABR Capital Management LLC Makes New $7.36 Million Investment in Abbott Laboratories $ABT - MarketBeat
Moran Wealth Management LLC Sells 73,546 Shares of Abbott Laboratories $ABT - MarketBeat
ABT Stock Price, Quote & Chart | ABBOTT LABORATORIES (NYSE:ABT) - ChartMill
Abbott has positive drug-eluting scaffold data - Drug Delivery Business
Abbott Laboratories (ABT) Stock Down 3.4% -- Now Undervalued? GF Score: 87/100 - GuruFocus
Abbott Laboratories stock underperforms Tuesday when compared to competitors - MarketWatch
Abbott Laboratories Stock (ABT) Moved Down by 3.33% on Apr 21: Key Drivers Unveiled - TradingKey
Value Equity Index Fund's Abbott Laboratories(ABT) Holding History - GuruFocus
Abbott Laboratories Just Got Interesting: Dividend Yield Near 3% Signals Opportunity - Seeking Alpha
Abbott Laboratories stock hits 52-week low at 93.91 USD - Investing.com
Wall Street Refuses to Blink: 2 Healthcare Stocks at 52-Week Lows That Analysts Still Love - 24/7 Wall St.
Is the Options Market Predicting a Spike in Abbott Laboratories Stock? - Zacks Investment Research
UBS Sticks to Their Buy Rating for Abbott Laboratories (ABT) - The Globe and Mail
Ticino Wealth Buys Shares of 11,005 Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories (NYSE:ABT) Price Target Lowered to $135.00 at UBS Group - MarketBeat
Leerink Partners Lowers Abbott Laboratories (NYSE:ABT) Price Target to $106.00 - MarketBeat
Argus Has Lowered Expectations for Abbott Laboratories (NYSE:ABT) Stock Price - MarketBeat
Abbott Laboratories: Buy The Dip On This Dividend King (NYSE:ABT) - Seeking Alpha
Leerink Partners Adjusts PT on Abbott Laboratories to $106 From $119, Maintains Market Perform Rating - marketscreener.com
Argus Adjusts Price Target on Abbott Laboratories to $125 From $140, Maintains Buy Rating - marketscreener.com
Leerink cuts Abbott Labs stock price target on mixed results - Investing.com
애보트 래버러토리스 (ABT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
애보트 래버러토리스 주식 (ABT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Salvadori Daniel Gesua Sive | EVP AND GROUP PRESIDENT |
Mar 02 '26 |
Sale |
115.58 |
885 |
102,288 |
146,377 |
| Morrone Louis H. | EXECUTIVE VICE PRESIDENT |
Mar 02 '26 |
Sale |
115.58 |
1,144 |
132,224 |
76,843 |
| Moreland Mary K | EXECUTIVE VICE PRESIDENT |
Mar 02 '26 |
Sale |
115.58 |
613 |
70,851 |
104,291 |
| MCCOY JOHN A. JR. | VICE PRESIDENT AND CONTROLLER |
Mar 02 '26 |
Sale |
115.58 |
585 |
67,614 |
24,628 |
| Cushman Elizabeth C. | EVP, GC AND SECRETARY |
Mar 02 '26 |
Sale |
115.58 |
263 |
30,398 |
38,573 |
0.65%
5.56%
자본화:
|
볼륨(24시간):